Safety, Tolerability, Pharmacokinetics, and Exploratory Pharmacodynamics of Multiple Rising Doses of BI 144807 Powder for Oral Drinking Solution Over a Period of 14 Days in Otherwise Healthy Controlled Asthmatic Subjects in a Randomised, Double-blind, Placebo-controlled Trial
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2013
At a glance
- Drugs BI 144807 (Primary)
- Indications Asthma
- Focus Adverse reactions
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Aug 2012 Actual initiation date Jul 2012 added as reported by ClinicalTrials.gov.